Kendle International — Investor Presentation (May 2005)
27 slides from Kendle International's investor presentation, May 31, 2005
Slide 1: Kendle on the Move
Real people. Real results. Kendle Kendle on the Move as of March 31, 2005
Slide 2: Safe Harbor
Real people. Real results. Safe Harbor Information herein contains forward-looking statements pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements are based largely on management’s expectations and are subject to risks and
Slide 3: Global Clinical Development Arena
Real people. Real results. Ke dl Global Clinical Development Arena ¢ Estimated total CRO market opportunity for 2005 is $13.0 billion to $15.0 billion ¢ Outsourcing Penetration — 2005 estimated at 21% to 28% ¢ Projected CAGR for the CRO market is approximately 14.0% 2003-2008 ¢ Outsourced spending e
Slide 4: Traditional Drivers of Outsourcing
Real people. Real results. Ke dl Traditional Drivers of Outsourcing ¢ Increase in pharmaceutical R&D spending (compared to lows of 2003) ¢ Biotech investment ¢ Increases in study size and complexity ¢ Concerns over drug safety testing — calls for more thorough testing and increased safety surveillan
Slide 5: Changing Outsourcing Environment
Real people. Real results. Ke dl Changing Outsourcing Environment * Consolidation of pharmaceutical industry ¢ Desire to work with fewer providers to the benefit of global, full-service providers An increase in the use of preferred provider agreements Patient recruitment becoming key issue — Demand
Slide 6: The Kendle View: Global Quantitative Research
Real people. Real results. Ke dl The Kendle View Kendle Global Quantitative Research * Quantitative survey conducted September 2004 ¢ Respondents included senior-level decision makers at pharmaceutical and biotechnology companies who outsource clinical trials ¢ A total of 300 in-depth telephone inte
Slide 7: The Kendle View: If increase, what phases?
Real people. Real results. The Kendle View Kendle If increase, what phases? Don't Know Phase 1 studies [| 46% Decrease 2% 10% Phases 2 and 3 0 50% studies Stay the Same 38% Regulatory ° Services 35% a , rs | Base: 300 0% 20% 40% 60% 80% 100% Q14 Inthe next 2 years, do you think your company’s outsou
Slide 8: The Top Selection Criteria for a CRO
Real people. Real results.® Kendle The Top 5 Selection Criteria for a CRO are: 1. Project Management 2. Communication 3. Expertise 4. Delivery of milestones on time 5. Retention of patients *Kendle proprietary information, not to be disclosed in any way 8 North America * Europe + Asia/Pacific * Lati
Slide 9: Market Context for Kendle
Real people. Real results. Ke dl Market Context for Kendle Clinical Development Discovery Pre-Clinical Phase I, Il, Ill, IIIB, IV | Launch Growth Maturity Decline Commercialization ¢ Kendle is one of the world’s leading clinical development organizations * Kendle competes in the Phase I-IV market va
Slide 10: Optimizing Customer Relationships
Real people. Real results.® Kendle Optimizing Customer Relationships Value Preferred Provider Integration 10 North America * Europe + Asia/Pacific * Latin America * Africa | i
Slide 11: Corporate Imperatives
Real people. Real results. Kendle Corporate Imperatives Develop Talent and Reward Performance
Slide 12: Kendle Core Competencies
Real people. Real results. Ke dl Kendle Core Competencies Kendle Biometrics Kendle Late Phase North America * Europe + Asia/Pacific * Latin America s+ Africa E__
Slide 13: Perceived Strengths for Kendle
Real people. Real results. Ke dl Perceived Strengths for Kendle High Importance/High Performance HIGHER A How customers see importance of indicators How customers rated Kendle performance LOWER > HIGHER *Kendle proprietary information, not to be disclosed in any way 13 North America * Europe * Asia/
Slide 14: Project Leadership at the Heart of Delivery and Communication
Real people. Real results. Kendle Project Leadership at the Heart of Delivery and Communication Full Accountability * CenterWatch recognition in 2003 Direct ¢ Winner of Pharmaceutical Times Access Enhanced Project Team of the Year, 2005 to Senior Kendle Communication Management Project Leader Proact
Slide 15: Staying Ahead of the Industry Trend
Real people. Real results. Kendle Staying Ahead of the Industry Trend Therapeutics Project portfolio aligned with industry clinical development priorities 1st 2nd Leadership within therapeutic areas: ¢ Adjunctive therapy in Oncology ¢ Inflammation development experience best in class ¢ Suite of Resp
Slide 16: Customer Loyalty - Key to Healthy Future
Real people. Real results. Ke dl Customer Loyalty - Key to Healthy Future Of Kendle customers responding to a worldwide customer satisfaction survey in January 2005*: Oo 90 No would recommend Kendle to a colleague Half of surveyed respondents report referral from a colleague as their primary source
Slide 17: Growth in Customer MSA Versus Prior Year
Real people. Real results.® Kendle Growth in Customer MSA Versus Prior Year 2003 2004 More strategic relationships lead to win/win efficiencies 17 North America * Europe + Asia/Pacific * Latin America s+ Africa | i
Slide 18: Growth in Number of RFPs Received
Real people. Real results.® Kendle Growth in Number of RFPs Received Large $ value awards +14% 2003 2004 18
Slide 19: Strong Growth in Net Sales
Real people. Real results.® Kendle Strong Growth in Net Sales [| oe |_| 2004 36 21 Qi Q2 Q3 Q North America * Europe + Asia/Pacific * Latin America s+ Africa | i $Million 4 19
Slide 20: Gross Book-to-Bill Ratio
Real people. Real results.® Kendle 2005 O Gross Book-to-Bill Ratio 2004 @ 2003 O 20 North America * Europe + Asia/Pacific * Latin Americas Africa | i
Slide 21: Financial Results
Financial Results NET SERVICE REVENUES* OPERATING INCOME* OPERATING MARGIN DILUTED EARNINGS PER SHARE NORTH AMERICAN REVENUE % * (000s) Rendle THREE MONTHS ENDED Mar. 31 2005 $47,687 $2,849 6.0% $0.16 57% 2004 $40,786 $696 1.7% $0.05 61% North America °* Europe «+ Asia/ Pacific * Latin America * Afr
Slide 22: Net Revenue Growth Comparison
Real people. Real results.® Kendle Net Revenue Growth Comparison Q1 2005 2004 13.5% Peer* Kendle Peer* Kendle Group Group * Peer Group includes Covance, PPD, Parexel, PRA and ICON. 22 North America * Europe + Asia/Pacific * Latin America s+ Africa | i
Slide 23: Operating Margin Comparison
Real people. Real results.® Kendle Operating Margin Comparison Q1 2005 2004 13.5% - 3.0% Peer Kendle Peer Kendle Group Group * Peer Group includes Covance, PPD, Parexel, PRA and ICON. 23 North America * Europe + Asia/Pacific * Latin Americas Africa | i
Slide 24: Financial Highlights
Real people. Real results. Kendle Financial Highlights Q1 2005 OPERATING CASH FLOW $4.1 million CASH AND AVAILABLE-FOR-SALE SECURITIES $32.1 million WORKING CAPITAL $43.4 million TOTAL ASSETS $159.4 million CREDIT FACILITY DEBT $9.2 million SHAREHOLDERS’ EQUITY $104.1 million 24 North America * Euro
Slide 25: 2005 Guidance
Real people. Real results.® Ke dl 2005 Guidance 2004 2005 est Growth Net Service Revenue* $172.9 $200 - $210 15.7% - 21.5% EPS $0.27 $0.65 — $0.70 140.7% - 159.3% * prt Millions 25 North America * Europe + Asia/Pacific * Latin Americas Africa | i
Slide 26: Why Invest in Kendle?
Real people. Real results. Ke dl Why Invest in Kendle? Significant improvement — Q1 2005 vs. Q1 2004 * New business awards of $73 million, up 38 percent * Total business authorizations of $256 million, up nearly 32 percent Net service revenues of $48 million, up 17 percent EPS grown to $0.16 per sha
Slide 27: Slide 27
Kendle International — Investor Presentation (May 2005) on 6ix